Category: by journal

Journal of the American Chemical Society retracts gold nanoparticle paper

On October 20, the Journal of the American Chemical Society retracted a 2009 paper. The retraction notice for “Single Gold Nanoparticles Counter: An Ultrasensitive Detection Platform for One-Step Homogeneous Immunoassays and DNA Hybridization Assays” was somewhat opaque:

This article is being retracted due to inaccurate DNA hybridization detection results caused by application of an incorrect data processing method. The authors regret any confusion that may have been created by the paper’s publication.

We contacted the paper’s lead author, Jicun Ren, of the College of Chemistry and Chemical Engineering, State Key Laboratory of Metal Matrix Composites, Shanghai Jiaotong University, to ask for more detail. He responded: Continue reading Journal of the American Chemical Society retracts gold nanoparticle paper

Obfuscation watch: Self-plagiarism (we think) leads to retraction of nanorod paper in Applied Physics Letters

C. P. Snow famously bemoaned the gulf between science and the humanities. The following retraction might be the sort of thing that would have given the physicist-cum-author fits for its estrangement from the English language.

Writing in the latest issue of Applied Physics Letters, a team from China Singapore and MIT appear to be confessing a case of self-plagiarism in their 2005 paper, “Growth of single crystal ZnO nanorods on GaN using an aqueous solution method: (we added a link to the earlier paper)” Continue reading Obfuscation watch: Self-plagiarism (we think) leads to retraction of nanorod paper in Applied Physics Letters

Penalties for early withdrawal: irked CONSORT Group authors

Premature withdrawal can lead to frustration and hurt feelings — especially when it comes to publications (please, this is a family-friendly site).

Two cases in point: We recently learned that the International Journal of Surgery, an Elsevier title, had withdrawn two papers from the CONSORT group — an acronym for Consolidated Standards of Reporting Trials — an international team of scientists who have been working on ways to improve the reporting of studies.

In 2008, they published a paper titled “Methods and processes of the CONSORT Group: example of an extension for trials assessing nonpharmacologic treatments” in the Annals of Internal Medicine. They followed up in March 2010 with the publication of “CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomized trials.”

As they wrote in the statement: Continue reading Penalties for early withdrawal: irked CONSORT Group authors

Journal will remove fake cardiologist William Hamman’s credentials, but paper will remain in print

Earlier this week, we asked what is likely to happen to papers published by William Hamman, the United pilot who claimed — falsely — to also be a cardiologist. Read more about the episode here.

One of the journals in which Hamman published, the American Journal of Medical Quality, will “amend the paper to correct” Hamman’s credentials — or lack thereof, a journal staffer told us today. The journal hasn’t dealt with this sort of thing before, so is checking with the publisher before making the change. They “plan to get it done as quickly as they can do it.”

We haven’t seen this sort of thing either. Continue reading Journal will remove fake cardiologist William Hamman’s credentials, but paper will remain in print

Catch Me If You Can: What happens to fake cardiologist William Hamman’s published papers?

photo of Frank Abagnale, Jr., whose story is the basis of Catch Me If You Can, by marcus_jb1973 via flickr http://www.flickr.com/photos/marcusjb/

It’s a mind-boggling story: A United Airlines pilot claims to be a cardiologist and was eagerly sought after for medical conferences at which he taught doctors teamwork. He shared millions in grants, according to the Associated Press. But as the AP reports, William Hamman wasn’t a cardiologist at all, having never even finished medical school.

Hamman’s career seems to be collapsing, now that he resigned from his post as a researcher and educator at Royal Oak, Michigan’s William Beaumont Hospital once the hospital found out he had misled them. (Just last year, Beaumont touted a $150,000 grant Hamman nabbed with a colleague, Marc Abramson at Improbable Research notes.) United has also grounded him.

The storyline is reminiscent of 2002’s Catch Me If You Can, in which Frank Abagnale Jr. (played by Leonardo DiCaprio) forges millions of dollars’ worth of checks around the world, in the process impersonating a Pan Am pilot and a doctor. In Hamman’s case, there are apparently no questions over whether his pilot credentials are legit, according to the AP.

Our interest at Retraction Watch is what happens to the papers Hamman has published over the years. There are at least six, including two published this year. The AP reported that Continue reading Catch Me If You Can: What happens to fake cardiologist William Hamman’s published papers?

A retraction in Neurology highlights an unusual practice

There’s a retraction in the issue of Neurology published this week. In a nutshell, a group of researchers had reported earlier this year that they had identified a genetic mutation potentially responsible for a rare neurological disorder called the filamin myopathy. But when another group tried to replicate those results, they found that the original tests were probably contaminated by a “pseudogene.”

In a letter from the second group:

Kono et al reported the effects of a novel c.8107del mutation in the filamin C gene (FLNC). We reviewed their results and concluded that the reported mutation was mistaken identity.

In a response, the authors thank the group and conclude: Continue reading A retraction in Neurology highlights an unusual practice

Update on the Gressner case: Son Olav says he’s the unfairly targeted “bête noire”

We have an update on the case of Olav and Axel Gressner, a father-son (or, in this case, son-father) pair of German liver researchers caught up in a fraud investigation. The inquiry focused on Olav, who left the University of Aachen under a cloud of suspicion. A 2008 research letter on which he was a co-author (his father was senior author) was retracted earlier this year by the Journal of Hepatology.

The journal’s position in the retraction notice,  published online in June and in print in September, bears repeating here. The authors: Continue reading Update on the Gressner case: Son Olav says he’s the unfairly targeted “bête noire”

Academic purgatory: Papers withdrawn before they’re “officially” published

If a paper appears online but then is withdrawn — a kinder, gentler version of retracted — before it is “officially” published, did anyone hear it fall?

Oops, mixed metaphors again. And scare quotes! The latter, however, are because publishers seem to have varying opinions of whether or not something that is freely available online is published. And that has ramifications for whether you can retract a paper like that.

Let us explain with two examples: Continue reading Academic purgatory: Papers withdrawn before they’re “officially” published

More on Anil Potti: Two other papers worth keeping an eye on

courtesy Duke

It’s fair to say that we haven’t heard the last of Anil Potti, the Duke cancer researcher who resigned last month following revelations that he had faked some of his results. Duke is still investigating the situation, and has also asked the Institute of Medicine to conduct its own study into the case and its ramifications.

This week, we may find out whether Nature Medicine will retract a paper that Joseph Nevins, one of Potti’s co-authors, asked the journal to withdraw last month. We’re also keeping an eye on two other papers that have already been the subject of increased scrutiny: Continue reading More on Anil Potti: Two other papers worth keeping an eye on

Our computer ate the data: Expression of concern over blood thinner study raises concerns itself

Thrombosis and Haemostasis has issued an “expression of concern” over a 2004 paper by Tunisian researchers:

Concerns have been raised by readers about the accuracy and validity of the data reported in the September 2004 article by Abdelkefi et al., entitled “Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease. A randomized controlled trial” (Abdelkefi A et al.Thromb Haemost 2004; 92: 654–661).

In the trial, 108 patients with blood cancers reportedly received infusions of either saline or heparin, a blood thinner. Those given the active drug were far less likely to develop clots related to their catheters, according to the researchers, and no more likely to experience severe bleeding. In the report, the researchers write:

This is the first prospective, randomized study, which shows that low-dose of unfractionated heparin is safeand effective to prevent catheter-related thrombosis in patients with haemato-oncological disease.

The article has had an impact, having been cited 32 times, according to Thomson Scientific’s Web of Knowledge. At some point after publication, however, the results evidently began to look fishy. Again from the journal: Continue reading Our computer ate the data: Expression of concern over blood thinner study raises concerns itself